Program for all days

• Remodel Overview - Framework And Key Outcomes
  PetterBjornstad Speaker petter.m.bjornstad@cuanschutz.eduUnited States
• Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial
  DavidCherney Speaker david.cherney@uhn.on.caCanada
• ACHIEVE
  MichaelWalsh Speaker lastwalsh1975@gmail.comCanada
• B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil
  JulienHogan Speaker julien.hogan2@aphp.frFrance
• Q&A Session

• ASPIRE (Aspirin in Dialysis PTS/ China): Large Pragmatic Trial
  XueqingYu Speaker yuxueqing@gdph.org.cnChina
• RESOLVE (NA CONCENTRTION IN DIALYSIS POPULATIONS: GLOBAL): CLUSTER RANDOMIZED TRIAL
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia
• VOICE
  ShuchiAnand Speaker sanand2@stanford.eduUnited States
• TEST PD
  JosephineChow Speaker Josephine.Chow@health.nsw.gov.auAustralia
• Renal Life Cycle
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far
  Selvin Sundar RajMani Speaker selvinsr@gmail.comIndia
• Q&A

• Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
  XiaobingYang Speaker yxb7829@163.comChina
• Evaluating the Effect of Sparsentan vs Irbesartan on Urine Inflammatory and Profibrotic Biomarkers in the Phase 3 Protect Trial of Patients With Immunoglobulin a Nephropathy
• Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III Applause-IgAN Study
  VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
• Q&A

• Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression
  VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
• Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression

• Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial (Tickers_hd)
  ClaraBohm Speaker cbohm@sogh.mb.caCanada
• Effect of Finerenone on Circulating Biomarkers: A Confidence Analysis
  MarioBerger Speaker mario.berger@bayer.comGermany
• Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the Confidence Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
  Naya Huang Speaker huangnaya@163.comChina

• Existing and Emerging Challenges to Providing Equitable and Sustainable Kidney Care
  AndrejSkoberne Speaker andrej.b.skoberne@gmail.comSlovenia
• Biological and Clinical Sex Differences in Kidney Health and Disease
  KateStevens Speaker kate.stevens@glasgow.ac.ukUnited Kingdom
• Opportunities for Delivering Equitable and Sustainable Kidney Care
  LuxiaZhang Speaker zhanglx@bjmu.edu.cnChina
• Q&A

• KDIGO Updates on Management of CKD Anemia
  WolfgangWinkelmayer Speaker winkelma@bcm.eduUnited States
• Global Disparities in CKD Anemia Management
  SunitaBavanandan Speaker sbavanandan@gmail.comMalaysia
• Beyond Erythropoiesis-stimulating Agents and Iron: Navigating the Future of Anemia of Chronic Kidney Disease Management
  Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deGermany
• Q&A

• Pre-test: Deep Dive Into the Indication of Genetic Testing, is the More the Merrier?
  RoserTorra Speaker rtorra@fundacio-puigvert.esSpain
• The Test: Nephro-genomic Board Simulation: Variant Scientist X Genetic Nephrologist
  DanielGale Speaker d.gale@ucl.ac.ukUnited Kingdom
• Risk Alleles and Low Penetrance Variants in Nephrology: The Gap in Evidence
  JanewitWongboonsin Speaker jwongboonsin@gmail.comThailand
• The Patient Voice
  SusieGear Speaker susiegear@alportuk.orgUnited Kingdom
• Q&A

• ISN Roles in Humanitarian Works
  AliAbu-Alfa Speaker abualfa@aub.edu.lbLebanon
• Preparedness for a Disaster: Pitfalls and Solutions
  SerhanTuglular Speaker serhantuglular@yahoo.comTurkey
• Earthquake Disaster: Lessons Learnt from Japan
  KeiFukami Speaker fukami@med.kurume-u.ac.jpJapan
• Resilient Kidney Care: Adaptation and Recovery After a Disaster
  SabineKaram Speaker sabinejkaram@gmail.comUnited States
• Q&A